Celdoxome pegylated liposomal Den Europæiske Union - dansk - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doxorubicinhydrochlorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiske midler - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Horisto 100+250 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

horisto 100+250 mg filmovertrukne tabletter

sandoz a/s - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 100+250 mg

Horisto 25+62,5 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

horisto 25+62,5 mg filmovertrukne tabletter

sandoz a/s - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 25+62,5 mg

Amiodarone "Orion" 50 mg/ml koncentrat til injektions-/infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

amiodarone "orion" 50 mg/ml koncentrat til injektions-/infusionsvæske, opløsning

orion corporation - amiodaronhydrochlorid - koncentrat til injektions-/infusionsvæske, opløsning - 50 mg/ml

Epirubicin "Accord" 2 mg/ml injektions-/infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

epirubicin "accord" 2 mg/ml injektions-/infusionsvæske, opløsning

accord healthcare b.v. - epirubicinhydrochlorid - injektions-/infusionsvæske, opløsning - 2 mg/ml

Epirubicin "Ebewe" 2 mg/ml injektions-/infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

epirubicin "ebewe" 2 mg/ml injektions-/infusionsvæske, opløsning

ebewe pharma ges.m.b.h. nfg. kg - epirubicinhydrochlorid - injektions-/infusionsvæske, opløsning - 2 mg/ml

Epirubicin "Fresenius Kabi" 2 mg/ml injektions-/infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

epirubicin "fresenius kabi" 2 mg/ml injektions-/infusionsvæske, opløsning

fresenius kabi oncology plc. - epirubicinhydrochlorid - injektions-/infusionsvæske, opløsning - 2 mg/ml